The correct dosage and use of olatrazumab (LARTRUVO)

Olaratumab (LARTRUVO) is a key intravenous infusion therapeutic drug. In clinical application, its specific usage and dosage are not static. Instead, a personalized plan must be accurately formulated by professional doctors based on the unique conditions of each patient.

For adult patients, there are clear recommendations for a routine initial dose: 15mg per kilogram of body weight. Generally, every 21 days constitutes a treatment cycle, and administration is performed on the 1 day and the 8 day of each cycle. It is worth mentioning that in the first 8 cycles of treatment, olaratumab needs to be used in combination with doxorubicin to exert a synergistic anti-cancer effect. At the beginning of treatment, the first injection is crucial and must be given under close supervision. This is because drugs may cause allergic reactions, and monitoring can ensure that they are detected at the first time and responded to quickly to ensure patient safety.

After initial treatment, a patient's maintenance dose is not fixed. Most patients can continue to use the 15 mg/kg dose, but doctors will pay close attention to the patient's individual response. If the patient tolerates the drug well, the original dose will be maintained; if intolerance occurs, the doctor will make appropriate adjustments based on the specific situation to ensure that the treatment is both effective and safe.

Olaratumab is administered via intravenous injection. During operation, the drug needs to be diluted with physiological saline or other suitable solutions, and then infused slowly intravenously. Slow infusion can effectively reduce the risk of drug reactions and ensure smooth treatment.

When administering the drug for the first time, close monitoring is the top priority, focusing on preventing allergic reactions. During subsequent doses, the patient's response also needs to be regularly evaluated to determine whether to continue treatment and whether dose adjustments are needed. Once an allergic reaction occurs during administration, especially during the first infusion, time must be taken to deal with it. If the reaction is severe, administration should be stopped immediately and appropriate first aid measures should be implemented quickly to protect the patient's life and health.

Reference materials:https://www.drugs.com/cdi/olaratumab.html